Add to ORKGIntroduction: The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, underscoring the need for novel antibiotics, particularly against methicillin-resistant S. aureus (MRSA). Telavancin is a bactericidal lipoglycopeptide with potent activity against Gram-positive pathogens. Objective: To systematically review and synthesize the available evidence from randomized controlled trials (RCTs) evaluating telavancin in the treatment of patients with infections due to Gram-positive organisms with the methodology o
BACKGROUND: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. METHODS: ...
Telavancin hadMIC50 andMIC90 values of 0.03 and 0.06g/ml (100.0 % susceptible), respectively, agains...
Telavancin (TLV) is a lipoglycopeptide derivative of vancomycin (VAN), which has activity against Gr...
INTRODUCTION: The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, unde...
Abstract: Telavancin is a lipoglycopeptide antibiotic with a dual mechanism of action; it disrupts b...
Purpose. The pharmacology, activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, ...
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and th...
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and th...
Abstract Background Staphylococcus aureus bacteremia is a common infection associated with significa...
Telavancin, a novel lipoglycopeptide with rapid concentration-dependent bactericidal effects, is a s...
Telavancin was the first marketed lipoglycopeptide. Although licensed in Europe in 2011 for the trea...
Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacte...
The activity of telavancin and comparators was assessed against a contemporary (2007 and 2008) globa...
Objectives: This study compared the activity of telavancin, a novel multivalent lipoglycopeptide wit...
Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin. Telavancin has a dual mecha...
BACKGROUND: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. METHODS: ...
Telavancin hadMIC50 andMIC90 values of 0.03 and 0.06g/ml (100.0 % susceptible), respectively, agains...
Telavancin (TLV) is a lipoglycopeptide derivative of vancomycin (VAN), which has activity against Gr...
INTRODUCTION: The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, unde...
Abstract: Telavancin is a lipoglycopeptide antibiotic with a dual mechanism of action; it disrupts b...
Purpose. The pharmacology, activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, ...
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and th...
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and th...
Abstract Background Staphylococcus aureus bacteremia is a common infection associated with significa...
Telavancin, a novel lipoglycopeptide with rapid concentration-dependent bactericidal effects, is a s...
Telavancin was the first marketed lipoglycopeptide. Although licensed in Europe in 2011 for the trea...
Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacte...
The activity of telavancin and comparators was assessed against a contemporary (2007 and 2008) globa...
Objectives: This study compared the activity of telavancin, a novel multivalent lipoglycopeptide wit...
Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin. Telavancin has a dual mecha...
BACKGROUND: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. METHODS: ...
Telavancin hadMIC50 andMIC90 values of 0.03 and 0.06g/ml (100.0 % susceptible), respectively, agains...
Telavancin (TLV) is a lipoglycopeptide derivative of vancomycin (VAN), which has activity against Gr...